SERTACIDE B Cream
Each gram contains:
Sertaconazole Nitrate BP …......................... 2% w/w
Beclomethasone Dipropionate, IP …........ 0.025% w/w
Cream base ….............................................. q. s.
Benzyl alcohol IP …..................................... 1.0% w/w (As preservative)
Sertaconazole is an antifungal that belongs to the imidazole class of antifungal agents.
Beclomethasone dipropionate is a synthetic halogenated corticosteroid with potent glucocorticoid activity but weak mineralocorticoid activity.
Sertaconazole is an antifungal that belongs to the imidazole class of antifungals and exhibits activity similar to that of other imidazoles. It is believed that they act primarily by inhibiting the cytochrome (CY) P450-dependent synthesis of ergosterol. Ergosterol is a key component of the cell membrane of fungi, and lack of this component leads to fungal cell injury, primarily by leakage of key constituents in the cytoplasm from the cell.
In clinical infections, sertaconazole nitrate has been shown to be active against isolates of dermatophytes (e.g. Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum).
Additionally, sertaconazole has demonstrated a broad spectrum of antifungal activity both in vitro and in experimental in vivo models, which includes opportunistic filamentous fungi (e.g. Aspergillus, Alternaria, Scopulariopsis, Fusarium), and pathogenic yeasts such as Malassezia furfur, Candida albicans, Candida tropicalis, Torulopsis, and Trichosporon. Activity has also been observed against Trichomonas and some Gram-positive organisms (staphylococci, streptococci).
Like other topical corticosteroids, beclomethasone dipropionate has anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of the anti-inflammatory activity of the topical corticosteroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase-A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase-A2. Beclomethasone is rapidly degraded enzymatically to a less active metabolite, significantly diminishing the possibility of systemic toxicity.
Sertaconazole achieves high epidermal concentrations following cutaneous application. Cutaneous absorption was 64% of the dose at 12 hours and 72% at 24 hours following topical application of a 2% cream. Systemic absorption is minimal to undetectable. The drug was undetectable in serum or urine samples from healthy subjects for up to 24 hours with 16 g of sertaconazole nitrate cream, 2%.
In a multiple-dose pharmacokinetic study that included 5 male patients with interdigital tinea pedis (range of diseased area, 42-140 cm2; mean, 93 cm2), sertaconazole nitrate cream, 2%, was topically applied to the diseased skin (0.5 grams sertaconazole nitrate per 100 cm2) every 12 hours for a total of thirteen doses. Sertaconazole concentrations in plasma, measured by serial blood sampling for 72 hours after the thirteenth dose, were below the limit of quantitation (2.5 ng/mL) of the analytical method used.
Beclomethasone is stated to be readily absorbed from sites of local application, and rapidly distributed to all body tissues. It is metabolized principally not only in the liver but also in other tissues, including the gastrointestinal tract and lungs; enzymatic hydrolysis rapidly produces the monopropionate and more slowly, the free alcohol, which is virtually devoid of activity. Only a small proportion of an absorbed dose is excreted in the urine, with the remainder being excreted in the faeces mainly as metabolites. When applied topically, particularly to large areas, when the skin is broken or under occlusive dressings, corticosteroids like beclomethasone may be absorbed in sufficient amounts to cause systemic effects.
For the topical treatment of fungal infections of skin with eczematous features.
Clean and dry the affected areas thoroughly before application of SERTACIDE B Cream.
Apply sufficient quantity of SERTACIDE B Cream to the affected skin areas twice daily. If no improvement is seen within 2 weeks, reassessment of the diagnosis may be necessary.
SERTACIDE B Cream is contraindicated in patients with a history of hypersensitivity to sertaconazole nitrate, beclomethasone dipropionate or any other component of the formulation.
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, with the potential for glucocorticoid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycaemia and glucosuria can also be produced in some patients by the systemic absorption of topical corticosteroids while on treatment.
Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the Adrenocorticotropic hormone (ACTH) stimulation, A.M. plasma cortisol, and urinary-free cortisol tests. Patients receiving super-potent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA suppression.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application or to substitute a less potent corticosteroid. Infrequently, signs and symptoms of glucocorticoid insufficiency may occur, requiring supplemental systemic corticosteroids.
Paediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratio.
It should also be avoided in patients with the following:
- History of allergic type responses to other topical or oral corticosteroids (enhanced risk of sensitivity).
- Evidence of pre-existing skin atrophy (exacerbation).
- Diabetes mellitus (potential hyperglycaemic action of topical steroid if there is sufficient absorption).
- Glaucoma or cataracts (potential worsening if there is sufficient absorption of topical steroid).
- Pregnancy or breastfeeding period (safety not clearly established).
- Liver failure as it may cause HPA axis suppression, Cushing's syndrome, hyperglycaemia or glycosuria.
- Active viral illnesses such as chicken pox or measles as a topical steroid may increase the risk of serious or fatal infection.
Potential interactions between sertaconazole nitrate cream, 2%, and other drugs or laboratory tests have not been systematically evaluated.
There are no reports of drugs interacting with topical beclomethasone dipropionate.
Animal reproduction studies of topical steroids have shown an adverse effect on the foetus and there are no adequate and well-controlled studies in humans, but the potential benefits may warrant use of the drug in pregnant women despite the potential risks.
There are no adequate and well-controlled studies that have been conducted on topically applied sertaconazole nitrate cream, 2%, in pregnant women.
Oral reproduction studies in rats and rabbits did not produce any evidence of maternal toxicity, embryotoxicity or teratogenicity of sertaconazole nitrate at an oral dose of 160 mg/kg/day (40 times in rats and 80 times in rabbits compared to the maximum recommended human dose on a body surface area basis).
Because animal reproduction studies are not always predictive of human response, sertaconazole nitrate cream, 2%, should be used during pregnancy only if clearly needed.
The safety and efficacy of sertaconazole nitrate and beclomethasone dipropionate cream has not been established in pregnant women. SERTACIDE B Cream is not recommended in pregnant women.
There is no clinical data available regarding the excretion of either sertaconazole nitrate or beclomethasone in breast milk. No effects on the lactating child are anticipated since the systemic exposure of the breastfeeding woman to sertaconazole nitrate or beclomethasone dipropionate is negligible following topical application. The use of SERTACIDE B Cream is not recommended in breastfeeding mothers.
Since safety and efficacy of sertaconazole nitrate and beclomethasone cream has not been established in paediatric patients below 12 years of age, its use in this age group is not recommended.
In clinical trials, cutaneous adverse events occurred in 7 of 297 (2%) patients (severe in two cases) receiving sertaconazole nitrate cream, 2%, and in 7 of 291 (2%) patients (severe in two cases) receiving vehicle. The reported cutaneous adverse events included contact dermatitis, dry skin, burning skin, application site reaction and skin tenderness.
In a dermal sensitization study, 8 of 202 evaluable patients tested with sertaconazole nitrate cream, 2%, and 4 of 202 evaluable patients tested with vehicle exhibited a slight erythematous reaction in the challenge phase. There was no evidence of cumulative irritation or contact sensitization in a repeated insult patch test involving 202 healthy volunteers.
In non-US postmarketing surveillance for sertaconazole nitrate cream, 2%, the cutaneous adverse events reported were contact dermatitis, erythema, pruritus, vesiculation, desquamation and hyperpigmentation.
Local reactions at the application site, including burning, irritation, pruritus and skin atrophy, may develop with fixed topical sertaconazole nitrate plus beclomethasone dipropionate cream. Most of these effects have been mild or moderate in severity. Discontinuation of therapy has been required in some patients due to local effects.
Undesirable effects observed for topical corticosteroids include (especially during prolonged application) the following: skin atrophy, telangiectasia, folliculitis, hypertrichosis, perioral dermatitis and adrenocortical suppression.
Topically applied sertaconazole nitrate and beclomethasone dipropionate cream may be absorbed in sufficient amounts to produce systemic effects. Excessive prolonged use of topical corticosteroids can suppress the pituitary adrenal function, resulting in secondary adrenal insufficiency
Appropriate symptomatic treatment is indicated in the event of overdosage. Acute hypercorticoid symptoms are virtually reversible. Treat electrolyte imbalance if necessary. In cases of chronic toxicity, slow withdrawal of corticosteroids is advised
Store below 25ºC. Do not freeze
SERTACIDE B Cream: Aluminium tube of 10 g
Last reviewed: November 2013